GSK can breathe easy as new CEO Emma Walmsley takes over, following the FDA rejection of Mylan’s generic version of big-selling respiratory drug Advair. The US patent on Advair (fluticasone ...
Even though Advair’s main patent expired in 2010 ... and the regulator had rejected Mylan’s generic last summer. However the regulator said at the time that there were only “minor ...
Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, ...
Jan 16 (Reuters) - Mylan has agreed to pay $73.5 million to settle a class action lawsuit by drug wholesalers accusing the drugmaker of scheming to overcharge them for EpiPen allergy treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback